Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and PK of [14C]-Empagliflozin in Healthy Males
NCT02172274Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum concentration of the analyte in plasma up to 144 hours, Time to maximum concentration up to 144 hours and 14 more. Started Jun 2008; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02172274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172274.